Sign In
Buy RPTX
$2.65
+0 (+0%)
At Close: Apr 24, 2026
Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
12:29pm, Monday, 27'th Jun 2022
Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data.
Repare Therapeutics stock is down as insiders flock to buy the $30-million RPTX dip
08:56am, Monday, 13'th Jun 2022
For the most part, biotech stocks have taken a beating this year, along with the broader market. The Nasdaq Biotechnology.
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
07:00am, Tuesday, 07'th Jun 2022
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that mem
Repare Therapeutics shares rise by 25% after it announced its collaboration deal with Roche
04:41am, Saturday, 04'th Jun 2022
Repare Therapeutics Inc (NASDAQ: RPTX), a top clinical-stage precision oncology corporation, announced that it's executed a collaboration and worldwide license deal with Roche for both the commerciali
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
04:33pm, Thursday, 02'nd Jun 2022
Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.
Why Repare Therapeutics Stock Is Skyrocketing Today
12:30pm, Thursday, 02'nd Jun 2022
The company just announced a major collaboration with multinational pharmaceutical giant Roche.
Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billion
08:00am, Thursday, 02'nd Jun 2022
Shares of Repare Therapeutics Inc. RPTX, -4.68% jumped 24.5% in premarket trading on Thursday, the day after the company said it signed a worldwide licensing and collaboration agreement with Roche Hol
Repare Therapeutics shares rise 18% after news of Roche deal
06:03pm, Wednesday, 01'st Jun 2022
Shares of Repare Therapeutics Inc. were trading higher in Wednesday's after-hours session, following news the company entered a worldwide license and collaboration agreement with Roche ROG, -1.13% to
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
09:49pm, Thursday, 05'th May 2022
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?
09:47am, Wednesday, 13'th Apr 2022
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
09:48am, Tuesday, 12'th Apr 2022
Repare Therapeutics Inc (NASDAQ: RPTX) presented updated data from its ongoing Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. The data were fe
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
01:00pm, Friday, 08'th Apr 2022
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has b
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.67% and 94.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
Repare Therapeutics (RPTX) Investor Presentation - Slideshow
02:40pm, Saturday, 12'th Feb 2022 Seeking AlphaRepare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
07:00am, Thursday, 03'rd Feb 2022
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar
